RT Journal Article
SR Electronic
T1 Using Whole Genome Sequencing to Characterize Clinically Significant Blood Groups Among Healthy Older Australians
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.04.18.21255241
DO 10.1101/2021.04.18.21255241
A1 Sudhir Jadhao
A1 Candice Davison
A1 Eileen V. Roulis
A1 Simon Lee
A1 Paul Lacaze
A1 Moeen Riaz
A1 John J McNeil
A1 David M Thomas
A1 Natalie M. Pecheniuk
A1 Catherine A. Hyland
A1 Robert L. Flower
A1 Shivashankar H. Nagaraj
YR 2021
UL http://medrxiv.org/content/early/2021/04/22/2021.04.18.21255241.abstract
AB There have been no comprehensive studies of a full range of blood group polymorphisms within the Australian population. The problem is compounded by the absence of any databases carrying genomic information on chronically transfused patients and low frequency blood group antigens in Australia. Here, we use RBCeq, a web server-based blood group genotyping software, to identify unique blood group variants among Australians and compare the variation detected versus global data. Whole genome sequencing data was analysed from for 2796 healthy older Australians from the Medical Genome Reference Bank and compared with data from 1000G phase 3 (1KGP3) databases comprising 661 African, 347 American, 503 European, 504 East Asian, and 489 South Asian participants. There were 688 rare variants detected in this Australian sample population, including nine variants that had clinical associations. Notably, we identified 149 variants that were computationally predicted to be novel and deleterious. No clinically significant rare or novel variants were found associated with the genetically complex ABO blood group system. For the Rh blood group system, one novel and 16 rare variants were found. Our detailed blood group profiling results provide a starting point for the creation of an Australian blood group variant database.Key pointsWe identified unique blood group variants among the healthy older Australian population compared with global data using RBCeq software.Our detailed blood group profiling result may be a starting point for the creation of an Australian blood group variant database.Competing Interest StatementThe authors have declared no competing interest.Funding Statement1) NSW Office of Health and Medical Research - Sydney Genomics Collaborative grant (2014). 2) National Institute on Aging and the National Cancer Institute at the National Institutes of Health (grant number U01AG029824); 3) The National Health and Medical Research Council of Australia (grant numbers 334047, 1127060) 4) Advance Queensland Research FellowshipsAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB00002519; ethics #2006/745MC The study was approved by the Alfred Hospital Research Ethics Committee (Project ID: 390/15) and registered on Clinicaltrials.gov 56 (NCT01038583). Participants provided biospecimens and written informed consent for genetic analysis.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe Medical Genome Reference Bank